Table I.
Characteristics of patients with IDHMUT with pre- and post-treatment samples available for comparison.
| Patient | Age | Sex | IDH mutation | Coexisting mutations* | Cytogenetics | Best response |
|---|---|---|---|---|---|---|
| A | 82 | F | IDH2 R140 | FLT-3–ITDMUT | NK | RD |
| NPM1MUT | ||||||
| B | 77 | M | IDH1 R132 | FLT-3–ITDMUT | NK | CR |
| C | 80 | F | IDH2 R140 | TET2MUT (S214X) | del(7) | CR |
| D | 70 | M | IDH1 R132 | None | NK | RD |
| E | 70 | M | IDH2 R172 | None | del(13q) | RD |
| F | 76 | F | IDH2 R140 | None | +8 | RD |
F, female; M, male; NK, normal karyotype; RD, resistant disease; CR, complete response.
*
All patients were screened for FMS-like tyrosine kinase 3 internal tandem duplication (FLT-3–ITD) and D835 tyrosine kinase domain mutation (FLT-3–TKD), nucleophosmin (NPM1), CCAAT enhancer binding protein alpha (CEBPA) and ten-eleven translocation 2 (TET2).